JNJ 64304500

Drug Profile

JNJ 64304500

Alternative Names: JNJ 64304500 AAA; JNJ-64304500

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease

Most Recent Events

  • 09 Sep 2017 Janssen Pharmaceutical completes a phase I trial in Crohn's disease (In volunteers) in Japan (SC) (NCT03002025)
  • 21 Dec 2016 Janssen Pharmaceutical plans a phase I trial in Healthy volunteers in Japan (SC) (NCT03002025).
  • 01 Dec 2016 Phase-I clinical trials in Crohn's disease (In volunteers) in Japan (SC) (NCT03002025)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top